Video interview with Gregg Fonarow, MD, explaining the success of the AHA Get With The Guidelines-Stroke program, during AHA 2024.

American Heart Association program leads to substantial improvements in stroke care

Cardiologist Gregg Fonarow, MD, reviewed decades of data and discussed the long-term impact of the AHA's Get With The Guidelines-Stroke program.

diet nuts legumes vegetables vegan vegetarian plant-based

Plant-based diets may help patients with diabetes, heart disease live longer

Researchers focused on data from nearly 78,000 adults with cardiometabolic disorders, sharing their findings at ACC.25 in Chicago.

An FDA panel will discuss its recommendations related to Abbott's TriClip G4 transcatheter edge-to-edge repair (TEER) system for tricuspid regurgitation.

First comprehensive T-TEER resource examines best practices for tricuspid valve repair

"We wanted to ensure that every interventionalist, regardless of location or resources, has access to the best information possible," one co-author said. 

Michael Reardon at ACC.25 presenting data on low-risk TAVR and SAVR patients

So far, so good: TAVR comparable to open heart surgery after 5 years in low-risk patients

Michael J. Reardon, MD, shared the highly anticipated data with a large audience at ACC.25 in Chicago. Overall, he said, these five-year findings suggest TAVR with a supra-annular, self-expanding valve is a safe and effective alternative to SAVR.

Darren K. McGuire, MD, discusses late-breaking data on oral semaglutide

Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’

Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.  

Semaglutide, the GLP-1 receptor agonist sold by Novo Nordisk under the brand names Wegovy and Ozempic, is associated with significant health benefits for patients with type 2 diabetes and peripheral artery disease (PAD), according to a late-breaking clinical trial presented at ACC.25, the annual meeting of the American College of Cardiology (ACC).

‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes

Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.

GE HealthCare Revolution Vibe CCTA

GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

healthcare policy reform government

ACC urges RFK Jr. to make Medicare reform a priority, warns against mass layoffs

The American College of Cardiology has sent a letter to HHS Secretary Robert F. Kennedy Jr. that outlines some of the organization’s central priorities and concerns.